8-K: Bausch Health Q3 2025 Revenue Up 7%, Raises Full-Year Guidance

Bausch Health Companies Inc. reported a 7% increase in third-quarter 2025 consolidated revenues to $2.68 billion and raised its full-year financial guidance.

Summary

• Consolidated revenues for Q3 2025 reached $2.68 billion, a 7% increase on a reported basis and 5% organically compared to Q3 2024.
• GAAP Net Income Attributable to Bausch Health was $179 million, a significant improvement from a net loss of $85 million in Q3 2024.
• Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP) grew 8% to $986 million, including an $81 million acquired In-Process Research & Development (IPR&D) charge.
• Bausch Health (excluding Bausch + Lomb) achieved its tenth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth.
• The company completed the acquisition of DURECT Corporation, expanding its hepatology portfolio with Larsucosterol, a novel epigenetic modulator with FDA Breakthrough Therapy Designation for alcohol-associated hepatitis (AH).
• Full-year 2025 guidance for Consolidated Revenue and Adjusted EBITDA, as well as Bausch Health (excluding Bausch + Lomb) Revenue, Adjusted EBITDA, and Adjusted Cash Flow from Operations, has been raised.

Sentiment

Score: 8

Explanation: The company reported strong revenue and EBITDA growth, a significant turnaround in GAAP net income, and raised its full-year guidance. Strategic acquisitions and R&D progress further bolster its position, despite some segment declines and ongoing industry risks like pricing controls and debt.

Positives

• Consolidated revenues increased 7% reported and 5% organically to $2.68 billion in Q3 2025 compared to Q3 2024.
• GAAP Net Income Attributable to Bausch Health improved significantly to $179 million in Q3 2025 from a net loss of $85 million in Q3 2024.
• Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP) rose 8% to $986 million in Q3 2025.
• Bausch Health (excluding Bausch + Lomb) achieved its tenth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth.
• Full-year 2025 financial guidance for consolidated revenue and Adjusted EBITDA has been raised.
• The acquisition of DURECT Corporation expands the hepatology portfolio with Larsucosterol, which has FDA Breakthrough Therapy Designation for alcohol-associated hepatitis.
• Salix segment reported strong revenue growth of 12% reported and 11% organic, primarily driven by Xifaxan's 16% revenue growth.
• Solta Medical segment demonstrated robust growth with revenues up 25% reported and 24% organic, led by performance in APAC, notably South Korea.
• The company strengthened its balance sheet by redeeming $601 million of 9.25% Senior Unsecured Notes due 2026 and repaying a $300 million receivables financing facility.
• Clear + Brilliant Touch, a fractionated laser device for skin resurfacing, received approval from Chinese National Medical Products in August 2025.

Negatives

• International segment reported a 2% decrease in revenues (4% organic decrease) in Q3 2025, partially offset by strength in EMEA.
• Diversified segment revenues decreased 4% reported (6% organic decrease) in Q3 2025.
• Consolidated cash provided by operating activities was flat at $405 million in Q3 2025 compared to Q3 2024.
• Higher interest expense of $412 million in Q3 2025 compared to $346 million in Q3 2024.
• Higher R&D expense and higher acquired IPR&D expense related to the acquisition of DURECT Corporation.

Risks

• Impact of current market and economic conditions, including inflation, on business and operations.
• Impact of pricing controls, such as the Inflation Reduction Act (IRA) and the Centers for Medicare & Medicaid Services (CMS) drug price negotiation program for Xifaxan, with initial price applicability in 2027.
• Uncertainty regarding the ability to complete the separation of Bausch + Lomb, including the timing, structure, and expected benefits, and potential related litigation.
• Uncertainty of commercial success for new and existing products.
• Challenges to patents and the company's ability to enforce and defend its Xifaxan intellectual property rights.
• Substantial debt and current and future debt service obligations.
• Potential imposition of and adverse changes to duties, tariffs, non-tariff barriers, and retaliatory trade protection measures.
• Uncertainties related to the DURECT acquisition, including expectations regarding margin expansion, accretion, deleveraging, and maintaining relationships with customers, suppliers, and business partners.
• Risks relating to potential diversion of management attention away from ongoing business operations.

Future Outlook

Bausch Health raised its full-year 2025 guidance for Consolidated Revenue to $10.050 $10.250 billion and Adjusted EBITDA to $3.570 $3.660 billion. For Bausch Health (excluding Bausch + Lomb), full-year guidance was also raised for Revenue ($5.000 $5.100 billion), Adjusted EBITDA ($2.700 $2.750 billion), and Adjusted Cash Flow from Operations ($0.975 $1.025 billion). The company anticipates top-line Phase 3 results for RED-C by early 2026 and is developing a Phase 3 program for Larsucosterol.

Management Comments

• "The third quarter marks our tenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, highlighting our team's consistent execution and operational excellence." Thomas J. Appio, Chief Executive Officer, Bausch Health.
• "The completion of our acquisition of DURECT Corporation in the quarter further strengthens our growth platform in R&D, complementing our existing hepatology pipeline and broadening the reach of our diverse portfolio across therapeutic areas and geographies." Thomas J. Appio, Chief Executive Officer, Bausch Health.
• "As we approach the close of 2025, we remain focused on executing against our strategic priorities, driving strong year-end performance, and unlocking value for shareholders." Thomas J. Appio, Chief Executive Officer, Bausch Health.

Industry Context

Bausch Health's strong Q3 2025 performance, particularly in its Salix and Solta Medical segments, indicates resilience in the gastroenterology and medical aesthetics markets. The acquisition of DURECT Corporation and its lead asset Larsucosterol, with FDA Breakthrough Therapy Designation for alcohol-associated hepatitis, positions the company for growth in the hepatology sector, a field with significant unmet medical needs. The continued growth of Bausch + Lomb also reflects a stable demand in the eye health market. However, the company acknowledges broader industry challenges such as pricing controls (IRA, CMS drug price negotiation for Xifaxan) and potential tariffs, which are significant headwinds across the pharmaceutical sector.

Comparison to Industry Standards

• NA

Legal Proceedings

• Ongoing legal and governmental proceedings, investigations, and information requests regarding certain legacy distribution, marketing, pricing, disclosure, and accounting practices.
• Challenges to patents and the company's ability to enforce and defend its Xifaxan intellectual property rights.
• Actual and potential litigation related to the proposed plan to separate its eye health business.

Stakeholder Impact

• Shareholders: Potential for increased value through strong financial performance, raised guidance, debt reduction, and strategic initiatives to unlock value from Bausch Health and Bausch + Lomb assets.
• Patients: Expansion of the hepatology portfolio with Larsucosterol (FDA Breakthrough Therapy Designation) and R&D progress in RED-C could lead to new treatment options.
• Employees: Continued operational excellence and growth may provide stability and opportunities.
• Creditors: Debt reduction initiatives (redemption of notes, repayment of facility) improve the company's balance sheet and debt maturity profile.
• Customers/HCPs: Continued product innovation and market presence in gastroenterology, eye health, and medical aesthetics.

Next Steps

• Execute against strategic priorities to drive strong year-end performance.
• Evaluate all options for unlocking shareholder value, including maximizing the value of Bausch Health and Bausch + Lomb assets.
• Anticipate top-line Phase 3 results for RED-C by early 2026.
• Continue development of the Phase 3 program for Larsucosterol for severe alcohol-associated hepatitis.
• Assess direct and indirect impacts of tariffs, non-tariff barriers, and trade protectionist measures.
• Mitigate the effects of pricing controls, including the Inflation Reduction Act and CMS drug price negotiation program for Xifaxan.

Key Dates

Recommendation

The company delivered strong Q3 2025 results, significantly improving GAAP net income and achieving robust revenue and Adjusted EBITDA growth. The tenth consecutive quarter of growth for Bausch Health (excluding Bausch + Lomb) demonstrates consistent operational execution. The raised full-year guidance signals management's confidence in continued performance. Strategic moves like the DURECT acquisition, bringing a Breakthrough Therapy Designated asset, and proactive debt reduction efforts further strengthen the company's long-term prospects. While risks such as pricing controls and substantial debt remain, the positive momentum and strategic actions suggest a favorable outlook for investors.

Keywords

Bausch Health, BHC, Q3 2025 Earnings, Financial Results, Pharmaceuticals, Eye Health, Bausch + Lomb, Salix, Solta Medical, DURECT Acquisition, Larsucosterol, Hepatology, Xifaxan, Revenue Growth, Adjusted EBITDA, Guidance Increase, Debt Reduction, SEC Filing, 8-K